These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 35027383)
1. Akatsuki disease in a patient using an epidermal growth factor receptor-tyrosine kinase inhibitor. Oda N; Nakagawa Y; Takata I BMJ Case Rep; 2022 Jan; 15(1):. PubMed ID: 35027383 [No Abstract] [Full Text] [Related]
2. Efficacy of Next-Generation EGFR-TKIs in Patients With Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials. Qi YT; Hou Y; Qi LC Technol Cancer Res Treat; 2020; 19():1533033820940426. PubMed ID: 32723164 [TBL] [Abstract][Full Text] [Related]
3. Concomitant Genetic Alterations With Response to Treatment and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With EGFR-Mutant Advanced Non-Small Cell Lung Cancer. Hong S; Gao F; Fu S; Wang Y; Fang W; Huang Y; Zhang L JAMA Oncol; 2018 May; 4(5):739-742. PubMed ID: 29596544 [TBL] [Abstract][Full Text] [Related]
4. Characteristics and overall survival of EGFR mutation-positive non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective analysis for 1660 Japanese patients. Inoue A; Yoshida K; Morita S; Imamura F; Seto T; Okamoto I; Nakagawa K; Yamamoto N; Muto S; Fukuoka M Jpn J Clin Oncol; 2016 May; 46(5):462-7. PubMed ID: 26977054 [TBL] [Abstract][Full Text] [Related]
5. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC. Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323 [TBL] [Abstract][Full Text] [Related]
6. Phase I study of TAS-121, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with non-small-cell lung cancer harboring EGFR mutations. Nishio M; Murakami H; Ohe Y; Hida T; Sakai H; Kasahara K; Imamura F; Baba T; Kubota K; Hosomi Y; Shimokawa T; Hayashi H; Miyadera K; Tamura T Invest New Drugs; 2019 Dec; 37(6):1207-1217. PubMed ID: 30790152 [TBL] [Abstract][Full Text] [Related]
8. ASP8273 tolerability and antitumor activity in tyrosine kinase inhibitor-naïve Japanese patients with EGFR mutation-positive non-small-cell lung cancer. Azuma K; Nishio M; Hayashi H; Kiura K; Satouchi M; Sugawara S; Hida T; Iwamoto Y; Inoue A; Takeda K; Ikeda S; Nakagawa T; Takeda K; Asahina S; Komatsu K; Morita S; Fukuoka M; Nakagawa K Cancer Sci; 2018 Aug; 109(8):2532-2538. PubMed ID: 29807396 [TBL] [Abstract][Full Text] [Related]
9. Which tyrosine kinase inhibitor should be recommended as initial treatment for non-small cell lung cancer patients with EGFR mutations? Tartarone A; Lerose R; Lazzari C; Gregorc V; Aieta M Med Oncol; 2014 Aug; 31(8):78. PubMed ID: 24958518 [TBL] [Abstract][Full Text] [Related]
10. Gefitinib in non small cell lung cancer. Costanzo R; Piccirillo MC; Sandomenico C; Carillio G; Montanino A; Daniele G; Giordano P; Bryce J; De Feo G; Di Maio M; Rocco G; Normanno N; Perrone F; Morabito A J Biomed Biotechnol; 2011; 2011():815269. PubMed ID: 21660144 [TBL] [Abstract][Full Text] [Related]
13. [Clinical research and drug review of epidermal growth factor receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer]. Zhou M; Chen DM; Xia L; Song YY; Shi YK; Yang ZM Zhonghua Zhong Liu Za Zhi; 2019 Dec; 41(12):949-952. PubMed ID: 31874554 [TBL] [Abstract][Full Text] [Related]
14. Impact on prognosis of rebiopsy in advanced non-small cell lung cancer patients after epidermal growth factor receptor-tyrosine kinase inhibitor treatment: a systematic review. Imakita T; Matsumoto H; Hirano K; Morisawa T; Sakurai A; Kataoka Y BMC Cancer; 2019 Jan; 19(1):105. PubMed ID: 30683066 [TBL] [Abstract][Full Text] [Related]